Amneal Pharmaceuticals is trading 5.89% lower at $19.02, with no confirmed catalyst for the decline.
- November 3 results beat analyst expectations, and management raised full-year 2026 guidance.
- One report said shares fell 3% immediately after the earnings release and suggested investors may have wanted more; that was the initial reaction, not today’s move.
- Major U.S. indexes are higher, so broad-market weakness does not explain the decline.